))
Optimizing First-Line Immunotherapy for Recurrent or Metastatic HNSCC
Manage episode 416273248 series 3381434
Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
CME credits: 0.50
Valid until: 03-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/program-name/24359/
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
…
continue reading
Valid until: 03-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/program-name/24359/
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
690 episodes
Share
